Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses

(2011) H.E. Campbell et al.   EUROPEAN JOURNAL OF CANCER

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

(2011) Angelo Di Leo et al.   LANCET ONCOLOGY

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

(2010) John MS Bartlett et al.   LANCET ONCOLOGY

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer 

(2008) M. W. RETSKY et al.   APMIS

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

(2008) H M Earl et al.   BRITISH JOURNAL OF CANCER